BRAF and cancer: Thus, our work provides a roadmap to determine whether early lesions in other cancer types that frequently have a similar genetic progression—an initial MAPK oncogenic driver mutation, including BRAF V600E, followed by a TPM—can similarly be classified into two groups that differentially engage OIS and RS.